China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by Proxima Ventures, with proceeds directed towards clinical studies, new adeno-associated virus (AAV) carrier design, pilot-scale production line construction, and expansion of the gene therapy pipeline.
Company Overview and Technology Platforms
Founded in 2021, View Gene Bio leverages its two core technologies—inducible gene therapy and tissue-specific gene therapy—to establish a rich product pipeline. The company’s pipeline covers hereditary eye diseases, skin diseases, and blood and central nervous system diseases. Additionally, Weiyou Gene Bio plans to utilize CRISPR-CAS technology to develop new gene therapies, further expanding its innovative therapeutic offerings.
Future Outlook
The pre-Series A funding marks a significant milestone for View Gene Bio as it seeks to advance its gene therapy programs. With the support of Proxima Ventures, the company is well-positioned to drive innovation in gene therapy, ultimately contributing to improved patient outcomes in various genetic disorders.-Fineline Info & Tech
